Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 12, 2025
Cell sorting based on single nucleotide variation enables characterization of mutation-dependent transcriptome and chromatin states.
Journal: Nucleic acids research
Published: November 07, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: July 02, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: June 18, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Journal: Nature medicine
Published: April 05, 2024
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
Journal: Nature medicine
Published: January 14, 2024
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 01, 2014
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.
Journal: The Journal of urology
Published: February 20, 2012
GM-CSF-armed, replication-competent viruses for cancer.
Journal: Cytokine & growth factor reviews
Published: April 13, 2010
Showing 1-10 of 10
Last Updated: 09/26/2026